

Biocatalysis

Deutsche Ausgabe: DOI: 10.1002/ange.201510331 Internationale Ausgabe: DOI: 10.1002/anie.201510331

25-Hydroxyvitamin D₃ Synthesis by Enzymatic Steroid Side-Chain Hydroxylation with Water

Markus Warnke, Tobias Jung, Juri Dermer, Karin Hipp, Nico Jehmlich, Martin von Bergen, Sascha Ferlaino, Alexander Fries, Michael Müller, and Matthias Boll*

Dedicated to Georg Fuchs on the occasion of his 70th birthday

Abstract: The hydroxylation of vitamin D_3 (VD₃, cholecalciferol) side chains to give 25-hydroxyvitamin D_3 (250HVD₃) is a crucial reaction in the formation of the circulating and biologically active forms of VD₃. It is usually catalyzed by cytochrome P450 monooxygenases that depend on complex electron donor systems. Cell-free extracts and a purified Mo enzyme from a bacterium anaerobically grown with cholesterol were employed for the regioselective, ferricyanide-dependent hydroxylation of VD_3 and $proVD_3$ (7-dehydrocholesterol) into the corresponding tertiary alcohols with greater than 99 % yield. Hydroxylation of VD₃ strictly depends on a cyclodextrinassisted isomerization of VD_3 into pre VD_3 , the actual enzymatic substrate. This facile and robust method developed for 250HVD3 synthesis is a novel example for the concept of substrate-engineered catalysis and offers an attractive alternative to chemical or O_2 /electron-donor-dependent enzymatic procedures.

Vitamin D₃ (VD₃, cholecalciferol, **1**) is generally known for its regulatory function in calcium and phosphorous homeostasis, but it is also recognized as an antiproliferative factor in dividing cells and tissues.^[1] VD₃ is formed from proVD₃ (7-dehydrocholesterol, **3**) by UV-B irradiation to give the *seco* form, followed by a thermal [1,7] sigmatropic hydrogen shift. It is converted into its biologically active form by consecutively acting cytochrome P450 monooxygenases (CYPs): hydroxylation in the liver yields 25-hydroxy-VD₃ (25OHVD₃, calcidiol, **2**), which is converted into calcitriol (1α,25(OH)₂VD₃) in the kidney. Insufficient levels of biologically active VD₃ are linked to numerous forms of cancer but

[*] M. Sc. M. Warnke, T. Jung, Dr. J. Dermer, K. Hipp, Prof. Dr. M. Boll Faculty of Biology - Microbiology
Albert-Ludwigs-Universität Freiburg
Schänzlestrasse 1, 79104 Freiburg (Germany)
E-mail: matthias.boll@biologie.uni-freiburg.de
S. Ferlaino, Dr. A. Fries, Prof. Dr. M. Müller
Institute of Pharmaceutical Sciences
Albert-Ludwigs-Universität Freiburg
Albertstrasse 25, 79104 Freiburg (Germany)
Dr. N. Jehmlich, Prof. Dr. M. von Bergen
Department of Proteomics
Helmholtz Centre of Environmental Sciences

Supporting information for this article (including experimental details) is available on the WWW under http://dx.doi.org/10.1002/anie.201510331.

Permoserstr. 15, 04318 Leipzig (Germany)

also to cardiovascular diseases, immunodeficiency, and diabetes. [2] 25OHVD₃ (2) represents the circulating form of VD₃, and its plasma concentration has been associated with VD₃-linked disorders. [3]

Classical chemical 25OHVD₃ (**2**) synthesis procedures involve multiple steps with low yields and specificities, ^[4] although recently more convenient procedures, for example, methods involving anchoring on a solid phase, have been developed. ^[5] For enzymatic synthesis, CYPs either from liver, fungi, or actinomycetes have been employed. ^[6] However, the dependence on complex electron-donor systems consisting of NAD(P)H, ferredoxin (Fd), and ferredoxin reductase (FdR) has limited biotechnological applications; promising approaches employ whole cells expressing the genes encoding CYP, Fd, and FdR (Scheme 1 A). As an alternative, an H₂O₂-dependent peroxygenase has been used for hydroxylation of low concentrations of VD₃ and ergocalciferol (VD₂; Scheme 1 B). ^[7]

Scheme 1. Enzymatic conversions of VD $_3$ (1) and proVD $_3$ (3) into 25OHVD $_3$ (2) and 25OHproVD $_3$ (4), respectively. A) Hydroxylation of 1 by O $_2$ -dependent CYPs in the presence of an electron-donor system including NAD(P)H, Fd, and FdR. B) Hydroxylation of 1 by H $_2$ O $_2$ -dependent peroxygenase. C, D) Water- and K $_3$ [Fe(CN) $_6$]-dependent hydroxylation of 1 and 3 by C25DH. (A) and (B) were previously established, (6,7) (C) and (D) were studied in this work.

A fundamentally different mode of enzymatic steroid side-chain hydroxylation was identified during the anaerobic degradation of cholesterol to CO₂ in the denitrifying bacterium *Sterolibacterium denitrificans*: the regioselective hydroxylation of cholesterol into 25-hydroxycholesterol with





water catalyzed by steroid C25 dehydrogenase (C25DH).[8] This enzyme belongs to the DMSO reductase (DMSOR) family of Mo enzymes that catalyze O2-independent hydroxyand oxo-transfer reactions. [9] A C-H bond functionalization with water to a tertiary alcohol via a carbocation transition state has been proposed.[8] C25DH transfers electrons to electrochemically regenerative electron acceptors such as $K_3[Fe(CN)_6]$ (Scheme 1 C). The genome of S. denitrificans contains at least eight homologous genes encoding putative Mo-dependent steroid hydroxylases, [8] thus making this organism a promising biological platform for water-dependent hydroxylations of various steroids. In this work, we explored the use of S. denitrificans enzyme(s) for regioselective synthesis of the biologically relevant hydroxylated forms of VD₃ (1) and proVD₃ (3). The hydroxylated 25OHproVD₃ (4, Scheme 1 D) can easily be converted into 25OHVD₃ (2) by established UV irradiation methods.[10]

In the presence of 2-hydroxypropyl- β -cyclodextrin (HPCD), crude extracts from *S. denitrificans* anaerobically grown with cholesterol catalyzed the $K_3[Fe(CN)_6]$ -dependent conversion of VD_3 (1) and $proVD_3$ (3) into the single products 2 and 4 (Figure 2 A, B), respectively, with substrate conversions of >99% (2) and 97% (4; Figure 1 A, B). After the




Figure 1. Enzyme assays for the hydroxylation of 1 and 3. A, B) Ultraperformance liquid chromatography (UPLC) analysis of the enzymatic conversion of 1 and 3 into their hydroxylated products 2 and 4, respectively. C, D) UV spectra of 1–4.

conversion of VD_3 (1) reached 92% (16 h), the product 2 was slowly degraded by unspecific enzymatic reactions, which could be fully prevented by the addition of 0.5 mm AgNO₃, a known inhibitor of the downstream reactions of steroid catabolism.^[8] The UV/Vis spectra of the products were identical to those of the substrates, which is in agreement with side-chain hydroxylations distant from the conjugated triene (1) and diene (3) chromophors (Figure 1 C, D).

Conversion of **1** and **3** was HPCD dependent, with an optimum at 15% (w/v; Figure 2C). The initial rate of the reaction followed Michaelis–Menten kinetics, with $v_{\text{max}} = 1.48 \pm 0.05 \text{ nmol min}^{-1}$ per mg crude extract protein for VD₃ (**1**), which is threefold higher than the rate of proVD₃ (**3**) conversion ($0.47 \pm 0.02 \text{ nmol min}^{-1}$ per mg crude extract protein; Figure 2D). The conversions of **1** and **3** were strictly




Figure 2. Properties of the enzymatic hydroxylation of 1 and 3. A) Time-dependent conversion of 1 into 2 in the presence of 0.5 mm $AgNO_3$. B) Time-dependent conversion of 3 into 4. Both reactions contained 15% HPCD C) HPCD dependence of the conversion of 1 and 3. D) Substrate concentration dependence of the conversion of 1 and 3.

dependent on electron acceptors with standard redox potentials higher than 200 mV, such as $[Fe(CN)_6]^{3-}$ (ferricyanide), with the highest initial rates between 5–10 mM $K_3[Fe(CN)_6]$. This rather high value can be explained by competing unspecific $K_3[Fe(CN)_6]$ oxidizing reactions in cell extracts.

The products formed from 1 and 3 were analyzed by chemical ionization mass spectrometry. For the product of 1 (M_r = 384.65), compound 2, an ion with m/z [M+H]⁺ of 401.3, was determined, thus indicating the addition of a hydroxy group (Figure S1 in the Supporting Information). Likewise, the conversion of 3 (M_r = 384.65) yielded a product with an identical m/z [M+H]⁺ (Figure S2). Both results strongly suggest the hydroxylation of VD₃ (1) and proVD₃ (3).

To unambiguously determine the regioselectivity of the reaction, the products were characterized by NMR spectroscopy. The 1 H and 13 C NMR spectra of authentic **1** and **3** standards were highly similar to their products **2** and **4**, respectively, with the exception of the chemical shifts for C26, C27 methyl groups (1 H spectra), and C25 (13 C spectra). For **1** and **3**, the C26 and C27 methyl groups are observed as doublets at $\delta = 0.86$ ppm in the 1 H spectra. For **2** and **4**, the 1 H NMR signal for CH₃-26,27 is observed as a singlet at $\delta = 1.23$ ppm. A downfield shift is observed in the 13 C NMR spectrum for the C25 signal ($\delta = 71.1$ ppm versus 22.8 ppm for **1** and **3**), thus indicating the hydroxylation of C25, as described for 25-hydroxycholest-4-en-3-one. [11]

The ¹H and ¹³C NMR spectroscopic data are in perfect agreement with those published for 25OHVD₃.^[14] The complete NMR spectroscopic data are presented in the Supporting Information (¹H and ¹³C NMR spectra/shifts, 2D NMR spectra for **2**, and ¹H NMR spectrum of **4**; Figures S3–S5 and Table S1).

To identify the enzyme(s) involved in VD_3 (1) hydroxylation, we enriched the activity from extracts of cells grown with cholesterol. After four chromatographic steps, four






Figure 3. Enrichment of the VD₃ (1) hydroxylating enzyme. A) Relative specific conversion rates of VD₃ (1, grey columns) and cholest-4-en-3-one (black columns) obtained during the solubilization and purification steps. a) cell extract; b) solubilized membrane fraction; c–f) fractions obtained after chromatography on DEAE-Sepharose, ceramic hydroxyapatite, Reactive Red agarose, and Mono Q anion exchange chromatography, respectively. B) SDS gel of enriched enzyme after four chromatographic steps. Left lane: bands 1–3 were identified as $\alpha\beta\gamma$ -subunits of C25DH; band 4 is a degradation product of band 1 (Table S2). Right lane: Molecular mass standard with masses in kDa as indicated.

protein bands were highly enriched with a specific VD_3 (1) hydroxylation activity of 80 nmol min⁻¹ mg⁻¹ (Figure 3 A). Mass spectrometric analysis of tryptic digests of the enriched protein bands identified the αβγ-subunits of C25DH (JQ292991-3) plus a fourth band corresponding to a degradation product of the α-subunit (JQ292991; Table S2). After each purification step, the relative specific hydroxylation rates of VD_3 (1) and cholest-4-en-3-one^[8] remained almost constant in all activity-containing fractions (around 70 % with 1), thus confirming that both reactions are catalyzed by the same enzyme (Figure 3 B). VD_3 (1) hydroxylation activity was highest in extracts of cells grown with cholesterol (100 %), and significantly lower in cells grown with sitosterol (18 %), ergosterol (15 %), or stigmasterol (5 %), which is in line with the induction of C25DH during growth with cholesterol.

The conversion of cholest-4-en-3-one and proVD₃ (3) by C25DH was observed in the presence of various detergents and HPCD. In contrast, conversion of VD₃ (1) was negligible when HPCD was replaced by a number of commonly used detergents (Figure S6). This finding suggests that HPCD plays a specific role in VD₃ conversion rather than serving as a general solubilizing agent. The equilibrium preVD₃ (5) \rightleftharpoons VD₃ (1) through thermal [1,7] sigmatropic rearrangement lies far to the right in aqueous detergent solutions (Scheme 2, upper reaction). However, in the presence of HPCD, an inclusion complex is formed at a 2:1 ratio (HPCD/VD₃), in which the thermodynamically unfavorable cZc conformer of preVD₃ (5) is stabilized. This finding led us to the assumption that preVD₃ (5) rather than VD₃ (1) is the actual substrate of C25DH.

By replacing the commonly used ethyl acetate for steroid extraction by n-hexane, more than 80% of VD_3 (1, 1 mm) added to the HPCD-containing assay mixture was identified as $preVD_3$ (5) by UPLC analysis. In the course of the enzymatic reaction, $preVD_3$ (5) was time-dependently converted into $25OHVD_3$ (2), with virtually no formation of the expected $25OHpreVD_3$ (6) intermediate (Figure 4). In con-

Scheme 2. Proposal for HPCD-dependent hydroxylation of VD₃ by C25DH. In the presence of HPCD, the equilibrium between VD₃ (1) and preVD₃ (5), which are interconverted through a thermal [1,7] hydrogen shift, is shifted to the right. The cZc conformer of 5 is likely the substrate for C25DH. The hydroxylated **6** was not detected owing to rapid isomerization to **2**.




Figure 4. UPLC analysis of enzymatic VD₃ (1) hydroxylation in the presence of HPCD after steroid extraction with n-hexane. At t = 0 h, before enzyme addition, around 80% of the added VD₃ was HPCD-dependently isomerized into preVD₃ (5).

trast, during extraction with ethyl acetate, $preVD_3$ (5) was never identified during VD_3 (1) hydroxylation (Figure 1 A). To substantiate the HPCD-dependent conversion of VD_3 (1) into $preVD_3$ (5) as an essential process for enzymatic sidechain hydroxylation, we replaced VD_3 (1) by authentic $preVD_3$ (5) and observed an identical product pattern as during VD_3 (1) conversion (Figure S7). The rates of VD_3 (1) and $preVD_3$ (5) hydroxylation were nearly identical, thus suggesting that the HPCD-dependent conversion of VD_3 (1) into $preVD_3$ (5) is not rate limiting.

In summary, the results indicate that $preVD_3$ (5) but not VD_3 (1) is the substrate for C25DH. The failure to detect any trace of a 25-OH-preVD₃ intermediate indicates a rapid isomerization into 25OHVD₃ (Scheme 2).

The procedure presented in this work represents a new enzymatic route for the regionelective hydroxylation of VD₃

1915

Zuschriften





(1), proVD₃ (3), and preVD₃ (5) at C25, and expands our knowledge of tertiary alcohol synthesis.^[13] Since cell extracts of S. denitrificans can be used for these reactions, it circumvents tedious enzyme purification or genetic manipulation procedures and offers a facile method for a mechanistically demanding chemical reaction. The method strictly depends on HPCD for VD₃ (1) solubilization and isomerization and represents a novel example of substrate-range expansion. In comparison to CYP-dependent hydroxylations it does not depend on electron-donor systems. The only cofactor used, $K_3[Fe(CN)_6]$, can be regenerated by electrodes as has been demonstrated for the related ethyl benzene dehydrogenase. [14] Moreover, the method does not depend on oxygen and nor is it oxygen sensitive. The synthetic method for 25OHVD₃ synthesis may be useful for the treatment of 25OHVD₃ deficiencies and to satisfy the increasing demand for monitoring of its levels in blood plasma.

Acknowledgements

This work was funded by DFG (BO 1565/11-1) in frame of the Scientific Priority Programme SPP1319. We thank Dr. P. Bisel, Freiburg, for help with NMR measurements.

Keywords: biotechnology \cdot C-H activation \cdot enzyme catalysis \cdot steroids \cdot vitamins

How to cite: Angew. Chem. Int. Ed. **2016**, 55, 1881–1884 Angew. Chem. **2016**, 128, 1913–1916

a) M. F. Holick, N. Engl. J. Med. 2007, 357, 266-281; b) S. V. Ramagopalan, A. Heger, A. J. Berlanga, N. J. Maugeri, M. R. Lincoln, A. Burrell, L. Handunnetthi, A. E. Handel, G. Disanto, S. M. Orton, C. T. Watson, J. M. Morahan, G. Giovannoni, C. P. Ponting, G. C. Ebers, J. C. Knight, Genome Res. 2010, 20, 1352-1360.

- [2] a) M. Wacker, M. F. Holick, *Nutrients* 2013, 5, 111–148; b) A.
 Hossein-nezhad, M. F. Holick, *Mayo Clin. Proc.* 2013, 88, 720–755
- [3] C. J. Farrell, S. Martin, B. McWhinney, I. Straub, P. Williams, M. Herrmann, *Clin. Chem.* **2012**, *58*, 531–542.
- [4] G. D. Zhu, W. H. Okamura, Chem. Rev. 1995, 95, 1877-1952.
- [5] D. Nicoletti, A. Mourino, M. Torneiro, J. Org. Chem. 2009, 74, 4782–4786.
- [6] a) K. Hayashi, H. Sugimoto, R. Shinkyo, M. Yamada, S. Ikeda, S. Ikushiro, M. Kamakura, Y. Shiro, T. Sakaki, *Biochemistry* 2008, 47, 11964–11972; b) K. Hayashi, K. Yasuda, H. Sugimoto, S. Ikushiro, M. Kamakura, A. Kittaka, R. L. Horst, T. C. Chen, M. Ohta, Y. Shiro, T. Sakaki, *FEBS J.* 2010, 277, 3999–4009; c) D. J. Kang, J. H. Im, J. H. Kang, K. H. Kim, *Bioprocess Biosyst. Eng.* 2015, 38, 1281–1290; d) D. J. Kang, J. H. Im, J. H. Kang, K. H. Kim, *Biotechnol. Lett.* 2015, 37, 1895–1904; e) T. Sakaki, H. Sugimoto, K. Hayashi, K. Yasuda, E. Munetsuna, M. Kamakura, S. Ikushiro, Y. Shiro, *Biochim. Biophys. Acta Proteins Proteomics* 2011, 1814, 249–256; f) K. Yasuda, M. Endo, S. Ikushiro, M. Kamakura, M. Ohta, T. Sakaki, *Biochem. Biophys. Res. Commun.* 2013, 434, 311–315; g) Y. Yasutake, T. Nishioka, N. Imoto, T. Tamura, *ChemBioChem* 2013, 14, 2284–2291.
- [7] E. D. Babot, J. C. Del Rio, M. Canellas, F. Sancho, F. Lucas, V. Guallar, L. Kalum, H. Lund, G. Grobe, K. Scheibner, R. Ullrich, M. Hofrichter, A. T. Martinez, A. Gutierrez, *Appl. Environ. Microbiol.* 2015, 81, 4130–4142.
- [8] J. Dermer, G. Fuchs, J. Biol. Chem. 2012, 287, 36905-36916.
- $[9]\ \ R.\ Hille,\ J.\ Hall,\ P.\ Basu,\ Chem.\ Rev.\ \textbf{2014},\ 114,\ 3963-4038.$
- [10] S. Fuse, Y. Mifune, N. Tanabe, T. Takahashi, Org. Biomol. Chem. 2012, 10, 5205 – 5211.
- [11] Y. R. Chiang, W. Ismail, M. Müller, G. Fuchs, J. Biol. Chem. 2007, 282, 13240 – 13249.
- [12] X. Q. Tian, M. F. Holick, J. Biol. Chem. 1995, 270, 8706-8711.
- [13] M. Müller, ChemBioEng. Rev. 2014, 1, 14-26.
- [14] P. Kalimuthu, J. Heider, D. Knack, P. V. Bernhardt, J. Phys. Chem. B 2015, 119, 3456-3463.

Received: November 6, 2015 Published online: December 22, 2015